Key Points
- Insider Daniel Wells purchased 38,717 Venture Life Group shares at an average price of GBX 65, for a total investment of approximately £25,166.
- Venture Life Group shares opened at GBX 65.81, with a market capitalization of £79 million and a 52-week trading range of GBX 52 to GBX 72.
- The company recently reported quarterly earnings of GBX 4.10 per share, alongside a 17.42% net margin and 7.82% return on equity; analysts expect full-year earnings of about GBX 6.14 per share.
Venture Life Group plc (LON:VLG - Get Free Report) insider Daniel Wells acquired 38,717 shares of the company's stock in a transaction that occurred on Wednesday, September 30th. The shares were acquired at an average price of GBX 65 per share, with a total value of £25,166.05.
Venture Life Group Stock Performance
Shares of Venture Life Group stock opened at GBX 65.81 on Thursday. The stock's fifty day moving average is GBX 67.41 and its two-hundred day moving average is GBX 65.09. The company has a market capitalization of £79.00 million, a PE ratio of 15.06, a price-to-earnings-growth ratio of 5.67 and a beta of 0.23. The company has a quick ratio of 1.48, a current ratio of 4.71 and a debt-to-equity ratio of 0.82. Venture Life Group plc has a 52 week low of GBX 52 and a 52 week high of GBX 72.
Venture Life Group (LON:VLG - Get Free Report) last released its earnings results on Tuesday, September 29th. The company reported GBX 4.10 earnings per share for the quarter. Venture Life Group had a return on equity of 7.82% and a net margin of 17.42%. As a group, analysts expect that Venture Life Group plc will post 6.1391542 earnings per share for the current year.
About Venture Life Group
(
Get Free Report)
Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life.
Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
